Clinical Trial Update: Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating lintuzumab-ac225 in combination with CLAG-M for relapsed/refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Cladribine (cladribine)
• Filgrastim (filgrastim)
• Lintuzumab-Ac225 (lintuzumab-actinium-225)
• Mitoxantrone (mitoxantrone)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED